共 50 条
Deep and Durable Response to Nivolumab and Temozolomide in Small-Cell Lung Cancer Associated With an Early Decrease in Myeloid-Derived Suppressor Cells
被引:8
|作者:
Owen, Dwight H.
[1
]
Benner, Brooke
[2
]
Pilcher, Carly
[3
]
Good, Logan
[2
]
Savardekar, Himanshu
[2
]
Norman, Ruthann
[2
]
Ghattas, Christian
[4
]
Shah, Manisha
[1
]
Konda, Bhavana
[1
]
Verschraegen, Claire F.
[1
]
Wesolowski, Robert
[1
]
Behbehani, Gregory K.
[5
]
Carson, William E.
[6
]
Otterson, Gregory A.
[1
]
机构:
[1] Ohio State Univ, James Canc Hosp, Solove Res Inst, Ctr Comprehens Canc,Dept Internal Med, 320 10th Ave,A450B Starling Loving Hall, Columbus, OH 43210 USA
[2] Ohio State Univ, James Canc Hosp, Solove Res Inst, Ctr Comprehens Canc, Columbus, OH USA
[3] Ohio State Univ, James Canc Hosp, Solove Res Inst, Clin Trials Off, Columbus, OH USA
[4] Ohio State Univ, Wexner Med Ctr, Dept Internal Med, Div Pulm Med, Columbus, OH USA
[5] Ohio State Univ, James Canc Hosp, Solove Res Inst, Ctr Comprehens Canc,Dept Internal Med, Columbus, OH USA
[6] Ohio State Univ, James Canc Hosp, Solove Res Inst, Ctr Comprehens Canc,Dept Surg, Columbus, OH USA
关键词:
Biomarker;
Chemotherapy;
Immunomodulation;
Immunotherapy;
Immune checkpoint inhibitor;
OPEN-LABEL;
PHASE-II;
T-CELLS;
RECURRENT;
EFFICACY;
CHEMOTHERAPY;
MULTICENTER;
EXPRESSION;
PROGNOSIS;
CARCINOMA;
D O I:
10.1016/j.cllc.2020.10.018
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
[No abstract available]
引用
收藏
页码:E487 / E497
页数:11
相关论文